AUTHOR=Kiffin Roberta , Grauers Wiktorin Hanna , Nilsson Malin S. , Aurelius Johan , Aydin Ebru , Lenox Brianna , Nilsson Jonas A. , Ståhlberg Anders , Thorén Fredrik B. , Hellstrand Kristoffer , Martner Anna TITLE=Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2 JOURNAL=Frontiers in Oncology VOLUME=8 YEAR=2018 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00218 DOI=10.3389/fonc.2018.00218 ISSN=2234-943X ABSTRACT=
In patients with acute myeloid leukemia (AML), treatment with histamine dihydrochloride (HDC) and low-dose IL-2 (HDC/IL-2) in the post-chemotherapy phase has been shown to reduce the incidence of leukemic relapse. The clinical benefit of HDC/IL-2 is pronounced in monocytic forms of AML, where the leukemic cells express histamine type 2 receptors (H2R) and the NAPDH oxidase-2 (NOX2). HDC ligates to H2Rs to inhibit NOX2-derived formation of reactive oxygen species, but details regarding the anti-leukemic actions of HDC remain to be elucidated. Here, we report that human NOX2+ myelomonocytic/monocytic AML cell lines showed increased expression of maturation markers along with reduced leukemic cell proliferation after exposure to HDC